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ER microdomains. It is noteworthy that 
certain ER proteins involved in the retro-
translocation process also partitioned into 
the lipid raft  fraction. Further studies are 
needed to determine whether there are 
innate diff erences in the effi  ciency of this 
final retro-translocation step between 
primary renal cells, such as GMVECs 
and MCs, and the more susceptible cell 
lines. Deficiency in either retrograde 
transport of Stx from the cell surface to 
the ER, or retro-translocation across the 
ER membrane into the cytosol, is likely 
to result in sublethal amounts of toxic 
StxA1 entering the latter compartment, 
limiting ribosomal damage. In some cell 
types — for example, intestinal epithelial 
cells and human umbilical vein endothe-
lial cells — sublethal toxin doses have 
been shown to elicit a so-called ‘ribotoxic 
stress response,’ which is characterized by 
increased production of new ribo somes 
and proinfl ammatory cytokines.12 Further 
research is needed to determine whether 
similar responses are elicited in renal 
cells such as GMVECs and MCs. This 
will throw further light on the relative 
contribution of direct Stx toxicity versus 
toxin-induced infl ammatory responses to 
the pathophysiology of hemolytic-uremic 
syndrome.
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Comprehensive suppression of the 
renin–angiotensin–aldosterone 
system in chronic kidney disease: 
Covering all of the bases
MH Weinberger1 and FC Luft2
Reducing proteinuria and blood pressure in chronic kidney 
disease (CKD) decreases rate of progression. Inhibition of the renin–
angiotensin system by angiotensin-converting enzyme inhibitors and/
or angiotensin receptor blockers is beneficial in reducing proteinuria 
but incomplete in suppressing aldosterone production and its renal 
effects. Adding aldosterone receptor blockers to these other agents 
may further halt the progression of CKD.
Kidney International (2006) 70, 2051–2053. doi:10.1038/sj.ki.5002007
Chronic kidney disease (CKD) has become 
a health burden of increasing proportions, 
with the numbers of patients continu-
ing to rise despite new pharmacological 
approaches to treatment. Lower blood 
pressure goals have been shown to be of 
great benefi t in slowing or halting the pro-
gression of CKD. A variety of interventions 
directed at inhibition of components of the 
renin–angiotensin system are known to be 
particularly useful. Despite these advances 
in treatment, beginning with the introduc-
tion of angiotensin-converting enzyme 
inhibitors (ACEIs) and, more recently, 
angiotensin receptor blockers (ARBs), the 
burden of CKD has continued to increase. 
Some have suggested a role for aldoster-
one synthesis ‘escape’ from inhibition of 
the renin system in CKD, which has led 
to the use of combination therapy with 
ACEIs plus ARBs to achieve more com-
plete inhibition of the renin–angiotensin–
aldosterone system. Although useful, this 
approach is only modestly eff ective. Per-
haps stimulated by the emerging evidence 
of direct vascular eff ects of aldosterone as 
well as eff ects on the heart and the kidney, 
and by the beneficial effects of adding 
inhibitors of aldosterone, such as spirono-
lactone1 and eplerenone,2 to multiple 
drug therapy in congestive heart failure, 
clinician-investigators have pursued the 
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notion that aldosterone blockade might 
off er an additional perspective. Bianchi 
and colleagues3 (this issue) report their 
long-term observations of the addition 
of spironolactone or placebo to treat-
ment of non-diabetic proteinuric CKD 
with ACEIs, ARBs, or their combination 
in over 150 subjects for 12 months. Th eir 
fi ndings provide several new insights that 
have potential importance for more eff ec-
tive treatment of such patients.
The issue of aldosterone synthesis 
‘escape’ seems to be only partially clarifi ed. 
Th e average basal level of aldosterone in 
the group of subjects receiving ACEIs plus 
ARBs was signifi cantly lower than that in 
subjects taking only one of these agents,3 
which suggests that the benefi cial eff ects of 
the combination in reducing proteinuria 
may result from more complete inhibition 
of the renin–angiotensin system. Although 
a role for bradykinin and other vasoactive 
factors has been postulated for the combi-
nation of ACEIs and ARBs, it remains to 
be demonstrated that a similar reduction 
in proteinuria could not have been pro-
duced simply by an increase in the dose 
of ACEIs or ARBs alone, rather than by 
some unique mechanism provided by 
the combination. On the other hand, the 
addition of spironolactone signifi cantly 
reduced proteinuria as compared with 
placebo. Th is eff ect was observed as early 
as 1 month after initiation when there 
was no change in blood pressure. Th e lat-
ter did not decline signifi cantly until aft er 
6 months of spironolactone addition. 
Importantly, although spironolactone 
reduced the estimated glomerular fi ltration 
rate at 1 month, at the end of 12 months 
the placebo group demonstrated a greater 
reduction in estimated glomerular fi ltra-
tion rate from baseline values and a sig-
nifi cantly higher blood pressure than the 
spironolactone group. It was disappointing 
to learn that less than half of the subjects in 
the study achieved the current goal blood 
pressures of less than 125/75 despite the 
use of multiple antihypertensive drugs and 
an aggressive approach to antihypertensive 
therapy by the investigators.3
Bianchi and colleagues3 found that 
the reduction in proteinuria seen with 
spironolactone was correlated with the 
aldosterone levels, confirming the fact 
that aldosterone is a component of the 
renal damage associated with CKD and 
that its inhibition by ACEIs, ARBs, or the 
combination is incomplete. However, the 
degree of reduction in proteinuria at the 
end of 12 months with spironolactone in 
the ACEI plus ARB group was less than 
with either agent alone, leaving unre-
solved the issue of aldosterone synthesis 
‘escape.’ It should be emphasized that the 
basal aldosterone level in the combination 
group was also lower than with ACEIs or 
ARBs alone.
The ‘predictors’ of the spironolac-
tone-related reductions in proteinuria at 
12 months, systolic blood pressure, basal 
aldosterone levels, and basal proteinuria, 
provide ‘food for thought’ regarding the 
treatment of proteinuric CKD. Because 
optimal reduction in systolic blood pres-
sure was not usually achieved, further 
lowering of blood pressure would seem to 
be desirable, suggesting the need to add 
even more drugs than were used in this 
study.3 Combination therapy with ACEIs 
plus ARBs was associated with lower 
basal aldosterone levels and lower basal 
proteinuria than either agent alone. Th is 
would argue for the benefi t of combination 
therapy or for the use of higher doses of 
these agents. One of the other factors that 
may have infl uenced the fi ndings is the 
changes in serum potassium, predictably 
greater in the spironolactone group and 
occurring within 1 month of initiation. 
Th is issue is of particular interest because 
of the benefi cial vascular eff ects of potas-
sium independent of changes in blood 
pressure.4
Direct eff ects of angiotensin II, and per-
haps renin itself, on aff erent and eff erent 
capillary tone have been well studied as fac-
tors infl uencing renal hemodynamics and 
renal vascular biology; aldosterone is also 
known to play a direct role. As an example, 
proteinuria is commonly seen in patients 
with primary aldosteronism, in whom the 
renin system and angiotensin II are typi-
cally markedly suppressed. Th us, an inde-
pendent role for aldosterone in modulating 
renal capillary pressure and its contribution 
to proteinuria is likely.
What, then, is the downside of aldo-
sterone inhibition with spironolactone in 
CKD patients treated with ACEIs and/or 
ARBs? Th e obvious fi rst concern would be 
for a substantial rise in serum potassium 
levels. Basal potassium levels were higher 
in ACEI plus ARB subjects than with 
either agent alone, confi rming the greater 
degree of aldosterone reduction with the 
combination.3 Spironolactone was associ-
ated with a signifi cant increase in serum 
potassium levels, but, despite the fact that 
all subjects were receiving ACEIs and/or 
ARBs, marked increases necessitating dis-
continuation of spironolactone were seen 
in only four subjects, all of whom had an 
estimated glomerular fi ltration rate less 
than 60 ml per minute per 1.73 m2, and 
three of whom were on both ACEIs and 
ARBs. Another anticipated side effect 
commonly seen with spironolactone 
was painful gynecomastia, which forced 
discontinuation in a single patient. Th e 
occurrence of this side eff ect is generally 
dose- and time-dependent. Th e dose used 
in this study, 25 mg per day, is the mini-
mal recommended dose, which may have 
diminished the frequency of this side eff ect 
in the study by Bianchi et al.3 Th e availabil-
ity of a more specifi c aldosterone recep-
tor antagonist, eplerenone, provides an 
alternative to spironolactone with a lower 
incidence of gynecomastia. Moreover, the 
latter has been evaluated among patients 
with diabetic nephropathy receiving ACEIs 
and has been shown to reduce proteinuria 
in a dose-dependent fashion.5
One other aspect of the renin–
angiotensin–aldosterone cascade is worthy 
of comment. A direct vasculotoxic role for 
renin has been postulated independent of 
its ability to generate angiotensin. Admin-
istration of ACEIs, ARBs, or aldo sterone 
antagonists, such as spironolactone or 
eplerenone, consistently results in an 
increase in renin release and concentra-
tion. Th e advent of direct renin inhibitors 
could add yet another therapeutic option 
to the interruption of this system and to 
the therapy of CKD in the future.
A fi nal comment should be made about 
the issue of aldosterone ‘escape.’ Th e release 
mechanisms for aldosterone are generally 
accepted to be angiotensin II and potas-
sium; a role for low sodium concentration 
is disputed, and adrenocorticotropic hor-
mone infl uences aldosterone production 
only when renin, and thus angiotensin II, 
are markedly suppressed. Recently an 
oxidized derivative of linoleic acid, 12,13-
epoxy-9-keto-10(trans)-octadecanoic 
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acid (EKODE), has been described.6 
EKODE stimulates aldosteronogen-
esis at concentrations as low as 0.5 µM. 
EKODE was found to mobilize calcium 
from stores in adrenal glomerulosa cells 
and subsequently to increase aldosterone 
secretion from adrenal cells via inositol 
1,4,5-triphosphate signaling.7 Th is work 
provides an important link between obes-
ity, the metabolic syndrome, and a novel 
stimulus for aldosterone production, inde-
pendent of classical angiotensin II- and 
potassium-dependent pathways. Work 
on novel mechanisms regarding aldoster-
one production and action, particularly in 
cardiovascular and renal cells, is an area of 
fascinating current research.
In summary, Bianchi and colleagues3 
provide convincing new evidence that 
aggressive reduction of systolic blood 
pressure and blockade of all components 
of the renin–angiotensin–aldosterone sys-
tem with the use of an aldosterone recep-
tor antagonist in addition to ACEIs and/or 
ARBs is useful in halting the progression 
of CKD. Monitoring of serum potassium, 
particularly in those with a reduced esti-
mated glomerular fi ltration rate less than 
60 ml per min per 1.73 m2, and of the other 
recognized side eff ects of the agents used, 
such as angioedema, cough, gynecomastia, 
and sexual dysfunction, is a required ele-
ment of careful follow-up.
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Asymmetric dimethylarginine in 
end-stage renal disease patients: 
A biomarker modifiable by 
calcium blockade and angiotensin 
II antagonism?
C Zoccali1
The nitric oxide synthase inhibitor asymmetric dimethylarginine 
(ADMA) is an emerging risk biomarker in  cardiovascular and renal 
diseases.  Apparently amlodipine and valsartan produce substantial 
reductions in the plasma concentration of this methylarginine in 
hemodialysis patients. These findings are of relevance for designing 
studies aimed at testing the etiologic relevance of ADMA to the high 
cardiovascular risk of ESRD.
Kidney International (2006) 70, 2053–2055. doi:10.1038/sj.ki.5001898
Cardiovascular disease and the attend-
ant risk of death and disabling compli-
cations in patients with chronic kidney 
disease are now legitimately considered 
as a major public-health problem. Th e 
astonishingly high diff erential in the risk 
of cardiovascular death between the end-
stage renal disease (ESRD) population 
and the general population cannot be 
overemphasized. Collectively, classical 
risk factors and comorbidities explain less 
than 50% of the variability in the risk of 
all-cause and cardiovascular mortality in 
this condition.1 For this reason, research 
on new cardiovascular risk factors and 
markers in patients with renal diseases 
is fl ourishing and also attracts investiga-
tors exterior to the realm of nephrology. 
Among new and emerging risk factors in 
ESRD, the nitric oxide synthase inhibitor 
asymmetric dimethylarginine (ADMA) 
has progressively gained center stage. 
Notwithstanding that this biomarker 
was tested just in one prospective cohort 
study,2 it is considered not only as an 
intriguing predictor of death and cardio-
vascular events but also as a likely causa-
tive factor of cardiovascular damage in 
this population. Interest in ADMA stems 
mainly from the fact that this compound 
perturbs a variety of physiologic functions 
that are notoriously altered in uremia 
(reviewed by Kielstein and Zoccali3).
Asymmetric dimethylarginine as a 
uremic toxin
ADMA has clear-cut cardiovascular 
eff ects in vivo in humans, and it appears 
likely that this methylarginine participates 
in the regulation of vascular tone.4 What 
makes ADMA almost unique among 
emerging cardiovascular risk factors 
is that this substance fulfi ls the criteria 
for being formally considered a uremic 
toxin.3 Cutting-edge studies by Kielstein et 
al. have nicely shown that in humans the 
administration of a sub-pressor dose of 
ADMA determines a 15% decrease in cer-
ebral perfusion.5 ADMA interferes with 
several hormonal systems; it is altered in 
clinical and subclinical hypothyroidism 
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